Supplementary tables for Estimated Vaccination Coverage with Selected Vaccines and Doses Among Adolescents Aged 13–17 Years, National Immunization Survey–Teen, United States, 2021

What to know

Supplementary vaccination coverage data from the NIS-Teen are included below. The first 2 tables show vaccination coverage for selected vaccines by race/ethnicity and by health insurance status. The final table shows change in estimates for bridging cohorts (2021 vs. 2021).

Supplemental Table 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by Race and Ethnicity— National Immunization Survey–Teen (NIS-Teen), United States, 2021.

Supplemental Table 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by Race and Ethnicity— National Immunization Survey–Teen (NIS-Teen), United States, 2021.
Vaccines Race and Ethnicity†, % (95% CI)§
White only, non-Hispanic
(n = 11,256)
Black only, non-Hispanic
(n = 1,799)
Hispanic
(n = 3,028)
American Indian/Alaska Native only, non-Hispanic
(n = 211)
Asian, non-Hispanic
(n = 779)
Multiracial, non-Hispanic
(n = 1,214)
Tdap ≥ 1 dose 90.1 ( 89.0 to 91.1) 90.6 ( 88.0 to 92.6) 87.4 ( 84.4 to 89.9) 96.0 ( 90.9 to 98.3) ** 91.5 ( 86.9 to 94.5) 90.5 ( 87.5 to 92.9)
MenACWY††
≥1 dose 89.2 ( 88.2 to 90.2) 90.2 ( 87.4 to 92.4) 86.5 ( 83.0 to 89.5) 93.4 ( 87.3 to 96.6) 95.6 ( 93.5 to 97.0) ** 88.1 ( 84.2 to 91.2)
≥2 doses§§ 61.3 ( 57.3 to 65.1) 61.7 ( 51.7 to 70.8) 50.6 ( 41.6 to 59.6) ** 63.8 ( 36.9 to 84.1) 78.8 ( 65.5 to 88.0) ** 57.5 ( 43.6 to 70.4)
HPV¶¶ vaccine
All Adolescents
≥1 dose 74.4 ( 72.8 to 75.9) 81.7 ( 78.2 to 84.7) ** 77.8 ( 74.2 to 81.1) 86.1 ( 78.4 to 91.4) ** 82.8 ( 77.4 to 87.1) ** 76.3 ( 69.4 to 82.1)
HPV UTD*** 59.8 ( 58.1 to 61.4) 65.0 ( 61.0 to 68.8) ** 61.7 ( 57.6 to 65.6) 75.4 ( 66.1 to 82.9) ** 72.3 ( 66.0 to 77.9) ** 58.1 ( 51.3 to 64.6)
FEMALES
≥1 dose 77.4 ( 75.3 to 79.4) 82.3 ( 77.1 to 86.6) 76.2 ( 70.4 to 81.1) 89.5 ( 81.3 to 94.3) ** 83.1 ( 74.6 to 89.1) 82.3 ( 76.4 to 86.9)
HPV UTD 63.1 ( 60.7 to 65.5) 66.9 ( 61.0 to 72.2) 60.5 ( 54.5 to 66.2) 80.0 ( 67.9 to 88.3) ** 74.4 ( 65.1 to 81.9) ** 61.4 ( 52.9 to 69.3)
MALES
≥1 dose 71.7 ( 69.4 to 73.9) 81.1 ( 76.3 to 85.1) ** 79.5 ( 74.7 to 83.5) ** 81.8 ( 67.2 to 90.7) 82.4 ( 75.6 to 87.6) ** 70.8 ( 59.1 to 80.2)
HPV UTD 56.7 ( 54.3 to 59.1) 63.2 ( 57.5 to 68.5) ** 62.9 ( 57.3 to 68.1) ** 69.5 ( 54.9 to 81.0) 69.5 ( 60.8 to 77.1) ** 55.0 ( 44.8 to 64.8)
MMR ≥2 doses 93.5 ( 92.5 to 94.3) 92.1 ( 89.1 to 94.3) 89.9 ( 87.0 to 92.3) ** 98.8 ( 96.2 to 99.7) ** 96.0 ( 93.8 to 97.4) ** 88.2 ( 80.1 to 93.2)
Hepatitis A vaccine ≥2 doses††† 83.8 ( 82.5 to 85.1) 83.2 ( 79.8 to 86.2) 86.6 ( 83.4 to 89.3) 95.6 ( 88.7 to 98.4) ** 92.8 ( 90.0 to 94.9) ** 82.7 ( 74.9 to 88.5)
Hepatitis B vaccine ≥3 doses 92.9 ( 92.0 to 93.8) 92.2 ( 89.7 to 94.2) 90.1 ( 86.9 to 92.5) 98.5 ( 94.2 to 99.6) ** 95.4 ( 93.3 to 96.9) ** 92.6 ( 89.2 to 95.0)
Varicella
History of varicella§§§ 7.5 ( 6.6 to 8.5) 4.8 ( 3.3 to 6.7) ** 7.1 ( 5.2 to 9.5) NA NA 8.8 ( 5.8 to 13.3)
No history of varicella disease
≥1 dose vaccine 96.0 ( 95.2 to 96.6) 95.9 ( 94.1 to 97.2) 93.0 ( 90.3 to 95.0) ** 97.9 ( 89.6 to 99.6) 97.1 ( 95.1 to 98.3) 90.3 ( 80.7 to 95.4)
≥2 doses vaccine 92.8 ( 91.8 to 93.7) 91.3 ( 88.3 to 93.6) 89.7 ( 86.6 to 92.1) ** 93.9 ( 87.2 to 97.2) 94.2 ( 90.6 to 96.5) 86.7 ( 78.0 to 92.3)
History of varicella or received ≥2 doses varicella vaccine 93.4 ( 92.4 to 94.2) 91.7 ( 88.8 to 93.9) 90.4 ( 87.6 to 92.7) ** 95.1 ( 89.5 to 97.8) 94.8 ( 91.5 to 96.9) 87.9 ( 79.8 to 93.0)

Abbreviations: CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up-to-date.

*Adolescents (N = 18,002) in the 2021 NIS-Teen were born January 2003 through January 2009.

† Adolescent's race/ethnicity was reported by their parent or guardian. Adolescents identified in this report as white, black, Asian, American Indian/Alaska Native, or multiracial were reported by the parent or guardian as non-Hispanic. Adolescents identified as multiracial had more than one race category selected. Adolescents identified as Hispanic might be of any race.

§ Estimates with 95% confidence intervals > 20 may not be reliable.

Includes percentages receiving Tdap vaccine at age ≥10 years.

** Statistically significant difference (p<0.05) in estimated vaccination coverage by race/ethnicity; referent group was adolescents non-Hispanic whites.

†† Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.

§§ ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents who were aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.

¶¶ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.

*** HPV UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated before age 15 years and there was at least 5 months minus 4 days between the first and second dose (https://www.cdc.gov/vaccines/programs/iis/cdsi.html). This update to the HPV recommendation occurred in December 2016.

†††In July 2020, ACIP revised recommendations for HepA vaccination to include catch-up vaccination for children and adolescents aged 2–18 years who have not previously received HepA vaccine at any age. MMWR Recomm Rep 2020;69(No. RR-5):1–38.

§§§ By parent/guardian report or provider records.

Supplemental Table 2. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by Health Insurance Status— National Immunization Survey–Teen (NIS-Teen), United States, 2021.

Supplemental Table 2. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by Health Insurance Status— National Immunization Survey–Teen (NIS-Teen), United States, 2021.
Vaccines Health Insurance Status†, % (95% CI)§
Private Insurance Only
(n = 11,378)
Any-Medicaid
(n = 5,269)
Other Insurance
(n = 1,312)
Uninsured
(n = 419)
Tdap ≥ 1 dose 90.2 ( 88.9 to 91.3) 89.6 ( 88.0 to 91.0) 87.4 ( 80.5 to 92.1) 84.7 ( 76.6 to 90.3)
MenACWY††
≥1 dose 90.2 ( 88.8 to 91.4) 88.8 ( 86.9 to 90.4) 85.5 ( 78.7 to 90.4) 77.5 ( 67.8 to 84.9)**
≥2 doses§§ 61.7 ( 57.3 to 65.9) 60.7 ( 54.7 to 66.4) 56.6 ( 45.1 to 67.5) NA
HPV¶¶ vaccine
All Adolescents
≥1 dose 75.9 ( 74.1 to 77.6) 80.5 ( 78.2 to 82.5)** 73.1 ( 66.8 to 78.5) 64.4 ( 54.3 to 73.4)**
HPV UTD*** 62.1 ( 60.2 to 64.0) 64.1 ( 61.3 to 66.7) 56.2 ( 50.1 to 62.1) 39.6 ( 30.4 to 49.6)**
FEMALES
≥1 dose 78.0 ( 75.4 to 80.4) 82.3 ( 79.4 to 84.9)** 71.7 ( 61.0 to 80.5) 61.6 ( 45.5 to 75.5)**
HPV UTD 64.3 ( 61.5 to 67.1) 66.2 ( 62.3 to 70.0) 58.9 ( 49.5 to 67.8) 35.0 ( 21.7 to 51.0)**
MALES
≥1 dose 73.8 ( 71.2 to 76.2) 78.8 ( 75.4 to 81.8)** 74.5 ( 68.3 to 79.8) 66.9 ( 54.2 to 77.5)
HPV UTD 59.9 ( 57.2 to 62.5) 62.1 ( 58.2 to 65.9) 53.3 ( 45.4 to 61.0) 43.6 ( 31.6 to 56.4)**
MMR ≥2 doses 93.2 ( 92.1 to 94.2) 91.2 ( 89.0 to 93.0) 92.9 ( 90.3 to 94.8) 84.9 ( 75.5 to 91.1)**
Hepatitis A vaccine ≥2 doses††† 85.6 ( 84.2 to 87.0) 84.8 ( 82.5 to 86.9) 86.7 ( 83.2 to 89.5) 71.1 ( 61.0 to 79.5)**
Hepatitis B vaccine ≥3 doses 93.6 ( 92.6 to 94.5) 91.3 ( 89.4 to 92.9)** 88.8 ( 81.6 to 93.4) 87.1 ( 78.5 to 92.6)
Varicella
History of varicella§§§ 6.4 ( 5.3 to 7.8) 8.5 ( 7.2 to 10.0)** 6.1 ( 4.4 to 8.3) 12.9 ( 8.1 to 19.9)**
No history of varicella disease
≥1 dose vaccine 95.9 ( 95.1 to 96.6) 93.6 ( 91.3 to 95.4)** 96.0 ( 93.9 to 97.4) 88.9 ( 78.7 to 94.5)
≥2 doses vaccine 92.6 ( 91.3 to 93.6) 90.5 ( 88.1 to 92.5) 91.8 ( 88.8 to 94.0) 83.5 ( 73.8 to 90.1)**
History of varicella or received ≥2 doses varicella vaccine 93.0 ( 91.9 to 94.0) 91.3 ( 89.1 to 93.1) 92.3 ( 89.5 to 94.4) 85.6 ( 77.0 to 91.4)**

Abbreviations: CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up-to-date.

*Adolescents (N = 18,002) in the 2021 NIS-Teen were born January 2003 through January 2009.

† Adolescents' health insurance status was reported by parent or guardian. "Other insurance" includes the Children's Health Insurance Program (CHIP), military insurance, Indian Health Service, and any other type of health insurance not mentioned elsewhere.

§ Estimates with 95% confidence intervals > 20 may not be reliable.

Includes percentages receiving Tdap vaccine at age ≥10 years.

** Statistically significant difference (p<0.05) in estimated vaccination coverage by health insurance status; referent group was adolescents with private insurance.

†† Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.

§§ ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents who were aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.

¶¶ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.

*** HPV UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated before age 15 years and there was at least 5 months minus 4 days between the first and second dose (https://www.cdc.gov/vaccines/programs/iis/cdsi.html). This update to the HPV recommendation occurred in December 2016.

†††In July 2020, ACIP revised recommendations for HepA vaccination to include catch-up vaccination for children and adolescents aged 2–18 years who have not previously received HepA vaccine at any age. MMWR Recomm Rep 2020;69(No. RR-5):1–38.

§§§ By parent/guardian report or provider records.

Supplemental Table 3. Change in Estimates* for Bridging Birth Cohort†, 2021 vs. 2020 National Immunization Survey – Teen

Supplemental Table 3. Change in Estimates* for Bridging Birth Cohort†, 2021 vs. 2020 National Immunization Survey - Teen
2021 Adequate Provider Data Definition
2020 2021 Difference P-value
for Test of
No
Difference
Variable Description Estimate Std
Err
Estimate Std
Err
Estimate Std
Err
P_U13TD 1+ Td/Tdap by 13 years 89.2 0.56 89.2 0.54 0.0 0.78 0.949
P_U13TDAP 1+ Tdap since age 10 by 13 years 86.0 0.63 85.5 0.60 -0.5 0.87 0.585
P_U13MEN 1+ MenACWY by 13 years 82.9 0.72 83.1 0.67 0.2 0.98 0.801
P_U13HPV 1+ HPV by 13 years 58.8 0.89 60.2 0.82 1.4 1.21 0.236
P_U13HPV3 3+ HPV by 13 years 8.8 0.41 9.4 0.53 0.6 0.67 0.370
P_U13HEPA 2+ Hepatitis A by 13 years 79.6 0.63 78.4 0.71 -1.2 0.95 0.214
P_U13HEPB 2+ or 3+ Hepatitis B depending on type by 13 years 91.8 0.67 91.2 0.56 -0.6 0.87 0.498
P_U13MCV 2+ Measles-containing by 13 years 92.1 0.45 91.3 0.55 -0.8 0.71 0.284
P_U13MMR 2+ MMR-containing by 13 years 91.6 0.46 91.0 0.55 -0.6 0.72 0.412
P_U13VRC 1+ Varicella by 13 years 94.1 0.38 93.2 0.47 -0.8 0.60 0.180
P_U13VRC2 2+ Varicella by 13 years 88.8 0.52 87.8 0.63 -1.0 0.81 0.219

Abbreviations: HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine.

*National-level estimates computed among children with adequate provider data, excluding children from U.S. territories.

† The bridging birth cohort used for this analysis for the 2020 and 2021 NIS-Teen is children born between January 2003 and December 2007. Final provider-phase weights for 2020 were ratio-adjusted within each monthly birth cohort such that their sum within monthly birth cohort equals the sum of the final provider-phase weights for 2021 within the corresponding monthly birth cohort.

An adolescent was considered to have adequate provider data if the adolescent had any non-COVID vaccination indicated by any PRC return (or was designated a zero-shot teen).